AERIUS TABLET
Land: Kanada
Språk: engelska
Källa: Health Canada
Produktens egenskaper
(SPC)
11-10-2022
Vissa dokument för denna produkt är för närvarande inte tillgängliga, du kan skicka en begäran till vår kundservice och vi kommer att meddela dig så snart vi kan få dem.
Skicka förfrågan.
Skicka förfrågan.
Aktiva substanser:
DESLORATADINE
Tillgänglig från:
BAYER INC
ATC-kod:
R06AX27
INN (International namn):
DESLORATADINE
Dos:
5MG
Läkemedelsform:
TABLET
Sammansättning:
DESLORATADINE 5MG
Administreringssätt:
ORAL
Enheter i paketet:
10/20/30/100
Receptbelagda typ:
OTC
Terapiområde:
SECOND GENERATION ANTIHISTAMINES
Produktsammanfattning:
Active ingredient group (AIG) number: 0143961001; AHFS:
Bemyndigande status:
APPROVED
Tillstånd datum:
2014-11-07
Produktens egenskaper
_ _
_ Desloratadine Syrup 0.5 mg/mL> _
_Page 1 of 40 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
AERIUS®
Desloratadine
Tablet, 5mg, Oral
USP
AERIUS® KIDS
Desloratadine
Syrup, 0.5 mg/mL Oral
Professed Standard
Histamine H1-Receptor Antagonist
Bayer Inc.
2920 Matheson Blvd. East
Mississauga, ON
L4W 5R6
Date of Revision:
October 11, 2022
Submission Control Number: 263344
®TM see www.bayer.ca/tm-mc
_ _
_ _
_ Desloratadine Syrup 0.5 mg/mL> _
_Page 2 of 40_
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
TABLE OF CONTENTS
...........................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.................................................................. 4
1
INDICATIONS....................................................................................................................
4
1.1
Pediatrics
..................................................................................................................
4
1.2
Geriatrics...................................................................................................................
4
2 CONTRAINDICATIONS
......................................................................................................
4
3 SERIOUS WARNINGS AND PRECAUTIONS
BOX..................................................................
4
4 DOSAGE AND ADMINISTRATION
......................................................................................
4
4.1 Dosing
Considerations....................................................................................................
4
4.2 Recommended Dose and Dosage
Adjustment.................................................................
4
4.3 Administration
...............................................................................................................
5
4.4 Mi
